November 28, 2025 | Insights, Patient first, The participation equation, clinical trials, patient engagement
Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

Clinical trials have never been more advanced – or more complex. With decentralised designs, digital tools, and new recruitment models reshaping the research landscape, one crucial element risks being lost: the human experience.
That’s why we wrote The participation equation. Developed in collaboration with the International Society for Patient Engagement Professionals (ISPEP), the report explores what truly drives people to join, stay in, and complete clinical trials. It’s about understanding participation not as a statistic, but as a story.
And at its heart, the project seeks to answer a simple but profound question – how can we make clinical research as meaningful for participants as it is for science?
Every good piece of research begins with curiosity. For us, the spark was an unanswered question.
As science and technology advance, what do trial participants really want and need from their experience?
To find out, we spoke directly to those who know best – the participants themselves. Through surveys with 700 people who have taken part in clinical research across the globe, in-depth interviews with 20 trial participants, and workshops with leading sponsors and researchers, we set out to uncover the lived realities of modern trial participation.
We wanted to go beyond recruitment numbers and retention rates to understand how participants feel – their motivations, frustrations, and triumphs. Because participation is not just a procedural act, it’s an emotional one.
Clinical research is changing rapidly. Hybrid and decentralised models are creating new opportunities for flexibility but also introducing new challenges. While trial designs become more sophisticated, participant experiences don’t always keep pace.
As our findings show, the gap between protocol intent and lived experience can sometimes undermine engagement. People may feel lost in logistics, burdened by travel, or frustrated by unclear communication. Yet when preferences are understood and acted upon, the benefits are measurable: higher completion rates, better data quality, and stronger trust between sponsors and participants.
Patient preference, then, isn’t just feedback, but evidence. Evidence that can help us design trials that are not only scientifically robust but also genuinely patient ready.
The participation equation was only possible thanks to collaboration between patients, sponsors, and organisations committed to transforming engagement.
Working with ISPEP and dozens of industry leaders from companies such as AstraZeneca, GSK, and Novartis, we were able to gather a truly 360-degree view of today’s trial experience. Each partner brought a vital perspective – patients shared what matters most, and industry voices explored how to make that insight actionable.
The result is a unique combination of quantitative data and qualitative depth, a conversation between science and empathy.
Behind every datapoint is a person. Someone juggling treatment schedules, family life, and uncertainty. Through the research, we heard stories of participants travelling hours each way for clinic visits or feeling anxious about data diaries and digital demands.
These insights revealed a powerful truth. Engagement is emotional. Feeling valued, supported, and informed can make the difference between dropping out and staying the course. Even small gestures, like personalised updates or thank-you notes, can build connection and trust.
Understanding these human factors isn’t a ‘nice-to-have’. It’s central to improving recruitment, retention, and data integrity. Most importantly, it ensures research honours the people who make it possible.
The participation equation is both a reflection and a call to action.
It shows that when we operationalise patient preferences, and when we treat people as partners rather than participants, we move closer to a future where every trial is designed with humanity at its core.
At Cuttsy+Cuttsy, this is the work we live for – turning insight into action, and data into difference. Because when we listen to what matters to people, we don’t just make research better, we make it meaningful.
Ready to dive deeper? Download The participation equation to explore the full findings, insights, and actionable recommendations.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...
Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. Find how to use colour effectively in your next clinical trial campaign.
With nearly a decade’s experience supporting clinical trials, find out why we think humanising trials through design is so important.
Throughout three fascinating days of conference, some key themes emerged that are impacting study teams and the effectiveness of their clinical trials on a daily basis.
As the Flexible Working Bill gets written into UK law, we took a look at what this means for businesses of all sizes and specialities.
